ROIV News and Press, Roivant Sciences Ltd. From 04/02/24

2024-04-02 17:15:03 ET Goldman Sachs analyst issues BUY recommendation for ROIV on April 2, 2024 03:55PM ET. The previous analyst recommendation was Buy. ROIV was trading at $10.92 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current a...

2024-04-02 17:00:03 ET Corinne Jenkins from Goldman Sachs issued a price target of $18.00 for ROIV on 2024-04-02 15:55:00. The adjusted price target was set to $18.00. At the time of the announcement, ROIV was trading at $10.92. The overall price target consensus is at $...

2024-04-02 09:20:47 ET More on Roivant Sciences Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success Roivant Sciences Ltd. (ROIV) Q3 2023 Earnings Call Transcript Chris DeMuth Sure Likes Uranium And SHF Holdings + 3 Litigation Ideas Roivant S...

Roivant’s board of directors has approved a share repurchase program for up to $1.5 billion of the company’s common shares, including an agreed repurchase of the entire Sumitomo Pharma stake for $648 million Sumitomo Pharma repurchase reduces shares outstanding by 9% In the ...

2024-03-28 13:46:05 ET More on Invesco S&P 500 Equal Weight ETF: RSP: Equal Weighting The S&P 500 To Minimize Magnificent Seven Exposure Is Not Optimal RSP: I Firmly Believe In An Allocation To Equal-Weight At This Juncture RSP: Happy 2024! Don't Make Decisio...

Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600 Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600 PR Newswire NEW YORK , March 26, 2024 /PRNewswire/ -- Roivant Sciences Ltd (NASD:ROI...

2024-03-18 15:52:57 ET Summary Roivant Sciences Ltd. has seen a slight gain of 10% in its stock over the past 10 months, since my "buy" recommendation last May. The company has a differentiated drug development pipeline targeting multi-billion dollar indications, thanks to its uni...

CNS Pharmaceuticals recently appointed Amy Mahery, a biotech commercialization leader, to its Board of Directors Ms. Mahery brings over 20 years’ experience, having worked with small and large companies, and has held diverse commercial leadership roles in the U.S. and globally The comp...

2024-03-06 17:09:23 ET Summary Baker Brothers' 13F portfolio value decreased from $17.35B to $8.79B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. New stakes include Cerevel Therapeutics, while stake disposals ...

2024-02-13 12:02:07 ET Roivant Sciences Ltd. (ROIV) Q3 2023 Results Conference Call February 13, 2024 08:00 AM ET Company Participants Stephanie Lee - Vice President, Special Projects Matt Gline - Chief Executive Officer Mayukh Sukhatme - President and Chief Inve...